Development of a modified live, canine origin parvovirus vaccine
Bass, E.P.; Gill, M.A.; Beckenhauer, W.H.
Journal of the American Veterinary Medical Association 181(9): 909-913
1982
ISSN/ISBN: 0003-1488 PMID: 7141990 Document Number: 191638
A modified live, canine parvovirus vaccine was tested for safety, efficacy, and clinical performance. The vaccine protected dogs from challenge with canine parvovirus (CPV) that caused clinical illness in all unvaccinated dogs. Vaccinated dogs developed CPV serum neutralization antibody, with a mean titre of 1664. Challenge virus was not recovered from vaccinated dogs, but it was recovered from faeces of unvaccinated dogs for up to four days after challenge. In a pathogenicity test, dogs inoculated orally with 10 times the label dose remained clinically normal. In tests for reversion to virulence, the vaccine strain remained non-pathogenic through six passages in seronegative test dogs. An immunological interference test demonstrated that test dogs developed antibodies for all antigens in a combined canine distemper virus-adenovirus 2-parainfluenza virus-parvovirus vaccine and a Leptospira interrogans serovars canicola and icterohaemorrhagiae bacterin. A total of 1 796 doses of the multivalent preparation was administered in a field study, with veterinarians reporting 36 local and five generalized reactions.